A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD

OBJECTIVES: Three Phase 3 trials have demonstrated the efficacy and safety of SPN-812 in pediatric subjects with ADHD. Here, we report the results of a fourth trial. METHODS: Eligible adolescent subjects (N = 297) were randomized to SPN-812 (400- or 600-mg/day) or placebo. The primary efficacy endpo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Psychopharmacol Bull
Main Authors: Nasser, Azmi, Liranso, Tesfaye, Adewole, Toyin, Fry, Nicholas, Hull, Joseph T., Chowdhry, Fatima, Busse, Gregory D., Melyan, Zare, Cutler, Andrew J., Findling, Robert L., Schwabe, Stefan
Formato: Artigo
Idioma:Inglês
Publicado em: MedWorks Media Global 2021
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8146561/
https://ncbi.nlm.nih.gov/pubmed/34092822
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados